期刊文献+

mTOR抑制剂在ADPKD中的应用

下载PDF
导出
摘要 常染色体显性多囊肾病(autosomal dominantpolycystic kidney disease,ADPKD)是人类最常见的遗传性肾病,其发病率为0.1%~2.5%,就诊多见于成人,其临床表现主要有肾脏体积增大、血尿、蛋白尿、高血压。其致病基因有3个,分别为PKD1、PKD2和PKD3,前两者均已被成功定位和克隆,而对PKD3的报道则较少。PKD1约占致病基因的85%,定位于16p13-3,编码分布于细胞膜的一种糖蛋白——多囊蛋白-1(polycystin-1,PC1)。PKD2约占致病基因的15%,定位于4q22~23,编码钙离子通道——多囊蛋白-2(polycystin-2,PC2)。PKD3约占致病基因的1%,由Daoust和de
作者 赵洁 夏庆华
出处 《泌尿外科杂志(电子版)》 2010年第2期37-39,共3页 Journal of Urology for Clinicians(Electronic Version)
  • 相关文献

参考文献19

  • 1崔心刚,俞能旺,安瑞华,王立明,梅长林,朱有华.西罗莫司延缓肾功能不全常染色体显性遗传性多囊肾病大鼠的疾病进程[J].第二军医大学学报,2006,27(11):1170-1173. 被引量:2
  • 2章海涛,季曙明.mTOR抑制剂的多效应作用[J].肾脏病与透析肾移植杂志,2006,15(2):188-191. 被引量:3
  • 3梅长林.常染色体显性遗传性多囊肾病研究的热点问题[J].第二军医大学学报,2003,24(1):1-4. 被引量:23
  • 4Salomé Almeida,Edgar Almeida,Dorien Peters,José Reim?o Pinto,Isabel Távora,Jo?o Lavinha,Martjn Breuning,Mateus Martins Prata.Autosomal dominant polycystic kidney disease: evidence for the existence of a third locus in a Portuguese family[J]. Human Genetics . 1995 (1)
  • 5Torres VE,Boletta A,Chapman Aet al.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol . 2010
  • 6Canaud KB,Hams PC,Vrtovsnik F,et al.Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease:what is the appropriate serum level[J ]. American Journal of Transplantation . 2010
  • 7Hogan MC,Masvuk TV,Page LJet al.Randomized clinical trial of long - acting somatostatin for autosomal dominant polycystic kidney and liver disease. Journal of the American Society of Nephrology . 2010
  • 8Edelstein CL.Therapeutic interventions for autosomal dominant poly-cystic kidney disease. Nephrology News and Issues . 2008
  • 9Serra AL,Poster D,Kistler AD,et al.Sirolimus and kidneygrowth in autosomal dominant polycystic kidney disease. The New England Journal of Medicine . 2010
  • 10Tao Y,Kim J,Schrier RW, et al.Rapamycin markedly slows disease progression in a rat modelof polycystic kidney disease. Journal of the American Society of Nephrology . 2005

二级参考文献66

  • 1Avery RK.Viral triggers of cardiac-allograft dysfunction.N Engl J Med,2001,344:1545-1547.
  • 2Wang X,Huong SM,Chiu ML,et al.Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus.Nature,2003,424:456-461.
  • 3Sanchez V,McElroy AK,Spector DH.Mechanisms governing maintenance of cdk1/cyclin B1 kinase activity in cells infected with human cytomegalovirus.J Virol,2003,77:13214-13224.
  • 4Trotter J,Wallack A,Steinberg T.Low incidence of cytomegaloirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid therapy.Transpl Infect Dis,2003,5:174-180.
  • 5Campistol JM,Gutierrez-Dalmau A,Torregrosa JV.Conversion to sirolimus:A successful treatment for posttransplantation Kaposi's sarcoma.Transplantation,2004,77:760-762.
  • 6Hall AV,Jevnikar AM.Significance of endothelial cell survival programs for renal transplantation.Am J Kidney Dis,2003,41:1140-1154.
  • 7Kovarik JM.Everolimus.A proliferation signal inhibitor targeting primary causes of allograft dysfunction.Drugs Today,2004,40:101 -109.
  • 8Hay N,Sonenberg N.Upstream and downstream of mTOR.Genes Dev,2004,18:1926-1945.
  • 9Abraham RT.Mammalian target of rapamycin:Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling.Curr Opin Immunol,1998,10:330-336.
  • 10Groth CG,Backman L,Morales JM,et al.Sirolimus (rapamycin)-based therapy in human renal transplantation:Similar efficacy and different toxicity compared with cyclosporine.Transplantation,1999,67:1036-1042.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部